Luyan Pharma Co.,Ltd. (SHE:002788)
China
· Delayed Price · Currency is CNY 14.81
-0.23 (-1.53%)
Mar 10, 2026, 9:25 AM CST
Luyan Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 20,840 | 20,398 | 19,785 | 19,406 | 17,508 | 15,499 | Upgrade
|
| Other Revenue | 72.73 | 72.73 | 60.56 | 56.58 | 37.16 | 36.03 | Upgrade
|
| Revenue | 20,913 | 20,471 | 19,846 | 19,463 | 17,545 | 15,535 | Upgrade
|
| Revenue Growth (YoY) | 2.09% | 3.15% | 1.97% | 10.93% | 12.94% | 3.51% | Upgrade
|
| Cost of Revenue | 19,419 | 18,948 | 18,339 | 17,950 | 16,179 | 14,308 | Upgrade
|
| Gross Profit | 1,494 | 1,523 | 1,506 | 1,512 | 1,366 | 1,227 | Upgrade
|
| Selling, General & Admin | 824.25 | 789.17 | 750.99 | 731.55 | 701.2 | 623.69 | Upgrade
|
| Research & Development | 6.48 | 5.85 | 5.53 | 4.15 | 2.97 | 3.77 | Upgrade
|
| Other Operating Expenses | 54.58 | 46.9 | 42.15 | 41.59 | 37.85 | 37.05 | Upgrade
|
| Operating Expenses | 873.58 | 838.39 | 811.62 | 809.68 | 765.63 | 676.89 | Upgrade
|
| Operating Income | 619.94 | 684.26 | 694.86 | 702.35 | 600.39 | 550.18 | Upgrade
|
| Interest Expense | -188.8 | -206.68 | -222.85 | -219.1 | -190.28 | -163.93 | Upgrade
|
| Interest & Investment Income | 3.07 | 3.84 | 5.14 | 3.86 | 5.18 | 3.47 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.95 | -0.95 | -0.03 | 0.1 | 0.01 | 0.04 | Upgrade
|
| Other Non Operating Income (Expenses) | -10.92 | -12.08 | -6.95 | -22.91 | -13.14 | -13.98 | Upgrade
|
| EBT Excluding Unusual Items | 422.34 | 468.38 | 470.16 | 464.3 | 402.15 | 375.78 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -1.89 | -17.5 | Upgrade
|
| Gain (Loss) on Sale of Investments | -16.64 | -18.73 | -12.16 | -6.92 | -2.14 | -2 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.23 | 0.17 | 0.28 | 0.13 | -0.53 | 0.03 | Upgrade
|
| Asset Writedown | -1.74 | -0.09 | -0.13 | -0.03 | -1.7 | -1.96 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -1.26 | Upgrade
|
| Other Unusual Items | 3.53 | 3.53 | 11.27 | 8.54 | 19.33 | 18.07 | Upgrade
|
| Pretax Income | 407.72 | 453.27 | 469.42 | 466.01 | 415.22 | 371.16 | Upgrade
|
| Income Tax Expense | 99.46 | 105.58 | 104.93 | 115.04 | 110.6 | 104.3 | Upgrade
|
| Earnings From Continuing Operations | 308.26 | 347.7 | 364.49 | 350.97 | 304.61 | 266.86 | Upgrade
|
| Minority Interest in Earnings | -0.3 | -2.05 | -0.96 | -5.82 | 1.26 | -0.24 | Upgrade
|
| Net Income | 307.96 | 345.64 | 363.53 | 345.16 | 305.87 | 266.63 | Upgrade
|
| Net Income to Common | 307.96 | 345.64 | 363.53 | 345.16 | 305.87 | 266.63 | Upgrade
|
| Net Income Growth | -14.19% | -4.92% | 5.32% | 12.84% | 14.72% | 4.20% | Upgrade
|
| Shares Outstanding (Basic) | 385 | 388 | 387 | 388 | 387 | 360 | Upgrade
|
| Shares Outstanding (Diluted) | 385 | 388 | 387 | 388 | 387 | 360 | Upgrade
|
| Shares Change (YoY) | -0.25% | 0.42% | -0.28% | 0.17% | 7.46% | 9.83% | Upgrade
|
| EPS (Basic) | 0.80 | 0.89 | 0.94 | 0.89 | 0.79 | 0.74 | Upgrade
|
| EPS (Diluted) | 0.80 | 0.89 | 0.94 | 0.89 | 0.79 | 0.74 | Upgrade
|
| EPS Growth | -13.98% | -5.32% | 5.62% | 12.66% | 6.76% | -5.13% | Upgrade
|
| Free Cash Flow | 337.61 | 216.36 | 779.91 | -95.4 | -615.51 | -110.35 | Upgrade
|
| Free Cash Flow Per Share | 0.88 | 0.56 | 2.02 | -0.25 | -1.59 | -0.31 | Upgrade
|
| Dividend Per Share | 0.350 | 0.350 | 0.300 | 0.300 | 0.300 | 0.200 | Upgrade
|
| Dividend Growth | 16.67% | 16.67% | - | - | 50.00% | 33.33% | Upgrade
|
| Gross Margin | 7.14% | 7.44% | 7.59% | 7.77% | 7.79% | 7.90% | Upgrade
|
| Operating Margin | 2.96% | 3.34% | 3.50% | 3.61% | 3.42% | 3.54% | Upgrade
|
| Profit Margin | 1.47% | 1.69% | 1.83% | 1.77% | 1.74% | 1.72% | Upgrade
|
| Free Cash Flow Margin | 1.61% | 1.06% | 3.93% | -0.49% | -3.51% | -0.71% | Upgrade
|
| EBITDA | 692.35 | 750.86 | 753.71 | 757.8 | 654.87 | 598.64 | Upgrade
|
| EBITDA Margin | 3.31% | 3.67% | 3.80% | 3.89% | 3.73% | 3.85% | Upgrade
|
| D&A For EBITDA | 72.41 | 66.6 | 58.85 | 55.45 | 54.48 | 48.46 | Upgrade
|
| EBIT | 619.94 | 684.26 | 694.86 | 702.35 | 600.39 | 550.18 | Upgrade
|
| EBIT Margin | 2.96% | 3.34% | 3.50% | 3.61% | 3.42% | 3.54% | Upgrade
|
| Effective Tax Rate | 24.39% | 23.29% | 22.35% | 24.69% | 26.64% | 28.10% | Upgrade
|
| Revenue as Reported | 20,913 | 20,471 | 19,846 | 19,463 | 17,545 | 15,535 | Upgrade
|
| Advertising Expenses | - | 4.06 | 1.27 | 1.94 | 1.7 | 1.47 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.